Toronto - December 9, 2008 - FOR IMMEDIATE RELEASE - Interface Biologics secures $5mm round of financing
Interface Biologics Inc. - a privately held developer of novel biomedical-polymers for use in implantable medical devices - is announcing that it h
Search
MEDIA
MEDIA - NEWS AND UPCOMING EVENTS
Media Contact:
Julie A. Fotheringham - Partner, Hageman Communications
Julie.fotheringham@hageman.ca 416-951-7988
Category: 2008
Interface Biologics' Anti-Thrombic Additives Show Equivalent Efficacy to Commercial Heparinized Coatings.
In a head to head comparison of Interface Biologics Inc. (IBI) Endexo Anti-thrombic additives versus commercially available heparin coated cathete
Medical device manufacturers are seeking alternatives to contaminated heparin coatings used to prevent thrombus in medical devices.